TY  - JOUR
A1  - Lucaciu, Alexandra
A1  - Brunkhorst, Robert
A1  - Pfeilschifter, Josef
A1  - Pfeilschifter, Waltraud
A1  - Subburayalu, Julien
T1  - The S1P–S1PR axis in neurological disorders - insights into current and future therapeutic perspectives
T2  - Cells
N2  - Sphingosine 1-phosphate (S1P), derived from membrane sphingolipids, is a pleiotropic bioactive lipid mediator capable of evoking complex immune phenomena. Studies have highlighted its importance regarding intracellular signaling cascades as well as membrane-bound S1P receptor (S1PR) engagement in various clinical conditions. In neurological disorders, the S1P–S1PR axis is acknowledged in neurodegenerative, neuroinflammatory, and cerebrovascular disorders. Modulators of S1P signaling have enabled an immense insight into fundamental pathological pathways, which were pivotal in identifying and improving the treatment of human diseases. However, its intricate molecular signaling pathways initiated upon receptor ligation are still poorly elucidated. In this review, the authors highlight the current evidence for S1P signaling in neurodegenerative and neuroinflammatory disorders as well as stroke and present an array of drugs targeting the S1P signaling pathway, which are being tested in clinical trials. Further insights on how the S1P–S1PR axis orchestrates disease initiation, progression, and recovery may hold a remarkable potential regarding therapeutic options in these neurological disorders.
KW  - sphingosine 1-phoshate
KW  - sphingosine 1-phosphate receptor
KW  - S1P1–5
KW  - sphingosine 1-phosphate metabolism
KW  - sphingosine 1-phosphate antagonistst/inhibitors
KW  - sphingosine 1-phosphate signaling
KW  - stroke
KW  - multiple sclerosis
KW  - neurodegeneration
KW  - fingolimod
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/55053
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-550534
SN  - 2073-4409
VL  - 9
IS  - 1515
PB  - MDPI
CY  - Basel
ER  -